## A NOVEL METHOD FOR THE ISOPRENYLATION OF B-DICARBONYL COMPOUNDS

h G. MIGNANI, D. MOREL and Y. COLLEUILLE

a) Centre de Recherches de Saint-Fons (Carrières) - RHONE-POULENC RECHERCHES BP 62 - 69192 - SAINT-FONS CEDEX - FRANCE b) Centre de Recherches de Vitry-sur-Seine - RHONE-POULENC SANTE BP 14 - 94400 - VITRY-SUR-SEINE CEDEX - FRANCE

r

## ABSTRACT :

The water-soluble composition rhodium/tris (sodium 3-sulfophenyl) phosphine (TPPTS) selectively catalyses the condensation of isoprene with active methylene compounds. An efficient synthesis of isofeprazone is described.

Many biologically active substances are "mero-terpenoids", i.e. contain in their structure an isoprenyl group (1), for instance, on the ring of a phloroglucinol sub-structure, or on the central atom of a  $\beta$ -dicarbonyl substrate. Synthesis of these structures is usually carried out by isoprenylation with the formal  $\chi, \chi$ -dimethylallyl cation (2). However different problems arise :

- A mixture of the monosubstituted and disubstituted compounds is obtained.
- Double bond isomerization : terminal and internal.
- Lack of regioselectivity because of the reactivity of the allylic cation at  $C_1$  or  $C_4$ .

We found that the use of isoprene as the alkylating agent and a catalyst comprised of a water-soluble phosphine developed in our laboratories (3), tris (sodium 3-sulfophenyl) phosphine (TPPTS) and rhodium-I, gave the required selectivity and regiospecificity efficiently.

Isoprene (1 equivalent) reacts at room temperature with barbituric acid (1 equivalent 1, in a  $H_20/CH_30H$  (75/25) mixture catalyzed by  $Rh/TPPTS/Na_2CO_3$ . Compounds 2 and 3 were isolated in 50 % overall yield and a 2/3 molar ratio of 35/65. 2 and 3 show numerous tautomeric forms in solution (4). Under our conditions, partial double bond isomerization was observed (5).



Meldrum's acid  $\underline{4}$  reacts under similarly mild conditions to give the monosubstituted derivative  $\underline{5}$  with no isomerization of the double bond (60% isolated yield) (6).



Taking advantage of this reaction, a new and efficient synthesis of isofeprazone <u>6</u> was developed, starting from isoprene and readily available 1,2 - diphenyl 3,5-dioxopyrazolidine (7). Isofeprazone <u>6</u> and especially its isomer feprazone <u>7</u> are potent anti-inflammatory substances with weak ulcerogenic properties (8).

5



Isomerization of  $\underline{6}$  to  $\underline{7}$  is easily carried out with Pd/C, PdCl<sub>2</sub>(PhCN)<sub>2</sub> type catalysts (5).

Under more vigorous conditions (100°C, 16 h,  $H_2O/C_2H_2OH$ ) double substitution occured, giving a mixture of isomers 8, 9 and 10 in quantitative yield (9).



The addition of activated methylene compounds to disymmetric dienes such as isoprene is generally poorly regioselective (10). However, the use of a RhI/ TPPTS system permits this reaction to be very selective with exclusive attack on the mono-substituted double bond. Since the catalytic system is water soluble, it is easily separated from the organic layer and recycled without any loss of activity.

Preparation of isofeprazone 6 : (11).

In a 500 ml round bottomed flask, was placed 55.5 g (220 mMol) 1,2-diphényl 3,5-dioxopyrazolidine, 0.41 g (Rh Cl COD)<sub>2</sub>, 6.02 g tris (sodium 3-sulfophenyl) phosphine and 1.5 g of Na<sub>2</sub>CO<sub>3</sub>. Air was replaced by argon and then 200 ml water, 50 ml methanol and 22 ml (220 mMol) isoprene were added. The reaction medium was magnetically stirred 48 H at 25°C. A white precipitate formed, which was filtered and washed with water. 61.7 g of 6 was obtained (87 % yield).

m.p. 128 - 130°C (lit. (8) 125-126°C).

Acknowledgment : We are grateful for the technical assistance of F. GRASS.

- (1) J.W. Cornforth, Chem. in Britain <u>4</u>, 102 (1968).
- (2) V.K. Ahluwalia, K.K. Arora, and R.S. Jolly, J. Chem. Soc. Perkin I, 335 (1982).
- (3) a) E.Kuntz (RHONE-POULENC) French Patent 2,314,910 (20.6.75).
  - b) RHONE-POULENC European Patent 44,771 (11.5.81).

(4) 
$$\underline{2} \text{ and } \underline{3} : H \text{ NMR} (360 \text{ MHz}, \text{ DMSO } d_6, \text{ ppm}, \text{ HMDS}) :$$
  
 $\underline{2} : \underbrace{CH_3}_{CH_3} (s) 1.47; \underbrace{CH_3}_{(s)} (s) 1.56 ;$   
 $- CH_2 - \underbrace{(d) 2.45}_{(s)} ; \underline{3} : \underbrace{(d) 1.90}_{(s)} (s) 1.57 ; CH_2 - \underbrace{(d) 1.90}_{(s)} (s) 1.90 \text{ et } 1.75 . \text{ IR } (\text{KBr, cm}^{-1}).$   
 $\vee C = 0 : 1770 - 1700 ; \forall \text{NH}(0\text{H}) : 3750 - 3200.\text{MS} : m/z(\%):264 (7), 221 (16), 196 (78), 141 (100), 128 (64), 69 (47), 56 (32), 42 (86), 41 (46).$ 

(6) a) 
$$5 : \text{m.p. 90°C, H NMR (360 MHz, CDCl_3, ppm, HMDS)} : \sum_{cH_2} CH_2 (s) 4.73$$
  
et 4.67; - CH\_3 (s) 1.68; - CH\_2 - CH\_2 - CH  $\leq$  (m) 2.20;  
- CH\_2 - CH\_2 - CH  $\leq$  (m) 2.20; - C - H (m) 3.48;  $\sum_{cH_3} CH_3 (s) 1.69 \text{ et}$   
1.72 IR (KBr, cm<sup>-1</sup>) v C = 0 : 1800-1750; v C = C : 1650.  $\delta C = CH_2 : 890.$   
MS : m/z (%) : 155 (25), 154 (27), 137 (33), 136 (35), 109 (23), 108 (22),  
95 (21), 82 (21), 81 (24), 68 (100), 67 (55), 55 (80), 43 (75),  
39 (33), 27 (69).

- b) Mitsui Petrochemical Industries, Ltd.Japanese Patent 8,059,181 (30.10.78)
- (7) a) H.Ruhkopf, Ber. <u>77</u>, 820 (1940)
  - b) M. Hruby Czechoslovak Patents 129,345 (15•10•68), 129,346 (15•10•68), 129,347 (15•10•68).
- (8) a) G.Pala, S. Casadio, E. Marazzi Uberti, B. Lumachi, E. Crescenzi, A.Donetti,
  A. Mantegani and C. Bianchi, Arzneim. Forsch. (Drug Res.) <u>22</u>, 171, 174,
  177, 183, 191 (1972).
  - (b) E. Cereda, E. Bellora and A. Donetti, Tetrahedron Lett 21, 4977 (1980).
  - (c) Istituto de ANGELI S.P.A. French Patent 2,515,646 (29.10.82).

- (9)  $\underline{8}, \underline{9} \text{ and } \underline{10}$ : HNMR (360 MHz, CDCl<sub>3</sub>, ppm , HMDS): - CH<sub>3</sub> (s), 1.49, 1.52, 1.62; -CH<sub>2</sub> - CH<sub>2</sub> (m) 1.98; - CH<sub>2</sub> - CH<sub>2</sub> (m) 1.98;  $\geq$  C = CH - CH<sub>2</sub> - (d) 2.56;  $\geq$  C = CH<sub>2</sub> (s), 4.61 et 4.62;  $\geq$  C = C<u>H</u> - CH<sub>2</sub> (t) 4.99; PHENYL 7.11 to 7.25. ratio  $\geq$  C = C  $\leq$  terminal/  $\geq$  C = C  $\leq$  internal = 1.6. IR (KBr, cm<sup>-1</sup>) vC = 0 : 1755 and 1720; vC = C : 1650; v C = CH<sub>2</sub> : 900; v Ar : 1600 and 1500; mono substitution : 700 and 760. MS : m/z (%) 388 (45), 320 (24), 265 (100), 264 (71), 212 (7), 211 (12), 195 (6), 183 (22), 77 (90), 69 (31), 41 (51).
- (10) R. Baker, Chem. rev. 73, 487 (1973).
- (11) <u>6</u> . HNMR (360 MHz, CDCl<sub>3</sub>, ppm, HMDS) : CH<sub>3</sub> (S)1.67 ; <u>H</u> (s) 4.70 ; - CH<sub>2</sub> - CH<sub>2</sub> - CH<sub>1</sub> - CH<sub>1</sub> - C - H (m) 2.23 - 2.17 ; - C - H (t) 3.36 ; Phenyl (m) 7.23 and (m) 7.09. IR (KBr, cm<sup>-1</sup>)  $\vee$ C = 0 : 1750 - 1720 ;  $\vee$ C = C : 1650 ;  $\vee$ C = CH<sub>2</sub> : 890 ; Phenyl : 1595 - 1490 / 700.750. MS : m/z (%) : 320 (29) , 265 (32), 264 (100), 252 (18), 184 (19), 183 (50), 105 (13), 77 (86).

(Received in France 28 February 1985)